ZyVersa Therapeutics, Inc. (ZVSA)
Oxford Ledge is still expanding full research coverage of ZVSA. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
ZyVersa develops two drug platforms for renal and inflammatory diseases, with VAR 200 in clinical trials and IC 100 in preclinical development.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Departure/election of directors or officers; Other material event 2026-07-10
- 10-Q Quarterly financial report (unaudited) 2026-05-13
- 10-K Annual financial report with audited statements 2026-03-31
- 8-K Entry into material agreement; Financial statements and exhibits 2026-03-05
- 8-K Departure/election of directors or officers 2025-12-03
Source: SEC EDGAR.
Annual results
4 years of annual figures for ZVSA, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | -$25.0M | -$4.18 |
| 2024 | — | -$9.4M | -$8.48 |
| 2023 | — | -$98.3M | -$1089.70 |
| 2022 | — | -$14.0M | -$0.99 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for ZVSA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open ZVSA in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.